Minggu, 17 April 2016

Venclexta

Unknown     06.54  No comments

FDA Approves Venclexta

The U.S. Food and Drug Administration (FDA) has granted accelerated approval of Venclexta (venetoclax), an oral B-cell lymphoma-2 (BCL-2) inhibitor for the treatment of patients diagnosed with chronic lymphocytic leukemia (CLL) with 17p deletion, as detected by an FDA-approved test, who have received at least one prior therapy.

Venclexta Medication Guide

Read this medication guide before you start treatment and every time you get a refill. There may be new information. If you have questions about this medicine, ask your healthcare provider or pharmacist.

Unknown


Lorem ipsum dolor sit amet, consectetuer adipiscing elit. Ut odio. Nam sed est. Nam a risus et est iaculis adipiscing. Vestibulum ante ipsum faucibus luctus et ultrices.
View all posts by Naveed →

0 komentar :

About U.S. Pharma Corporation

U.S. Pharma Corporation is headquartered in New Jersey but has research sites in Germany, France, the United Kingdong, Switzerland, and Australia. Research and development of new pharmaceuticals is key to ongoing profits, and U.S. Pharma researches and tests thousands of possible drugs. The company’s researchers need to share information with others within and outside the company, including the U.S. Food and Drug Administration, the World Health Organization, and the International Federation of Pharmaceutical Manufactureres & Associations. Also critical is Access to health information sites, such as the U.S. National Library of Medicine and to industry conferences and professional journals.